WAKEFIELD, Mass.–(BUSINESS WIRE)–Myrtelle Inc. (“Myrtelle” or the “Company”), a clinical stage gene therapy company focused on developing transformative treatments for neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track, Rare Pediatric Disease (RPD), and Orphan Drug designations for its lead clinical-stage gene therapy, rAAV-Olig001-ASPA, for the treatment of…
Read moreLatest News
Armen Asatryan joined Myrtelle in 2021, shortly after its inception, and has over 20 years of combined experience in pharma/biotech, public health, and clini- cal medicine. Prior to joining the com- pany, Armen held positions of increasing responsibility at Abbott/AbbVie, AveXis/ Novartis, and most recently at AVROBIO, where he was Vice President of Clinical Development…
Read moreMyrtelle’s Phase 1/2 clinical trial introduces first-of-its-kind proprietary recombinant adeno-associated virus (rAAV) vector designed to enable targeting of oligodendrocytes
Read moreMyrtelle’s gene therapy represents a first-of-its kind breakthrough treatment that utilizes a proprietary recombinant adeno-associated virus (rAAV) vector enabling robust targeting of oligodendrocytes, critical for myelination and brain development
Read moreMyrtelle Inc. targets Canavan disease with an exclusive worldwide licensing agreement with Pfizer Inc. for an investigational rAAV gene therapy.
Read moreDr. Robert Lober is a leading pediatric neurosurgeon and brain cancer researcher at Dayton Children’s Hospital.
Read more
